gp100-TCR retrovirus

The gp100-TCR retrovirus refers to an autologous T-cell therapy approach where a patient's peripheral blood lymphocytes (PBLs) are genetically engineered using a retroviral vector to express a T-cell receptor (TCR) specific for the gp100 melanoma-associated antigen. Specifically, the TCR is designed to recognize the HLA-A*0201-restricted epitope of gp100 (amino acids 154-162). This gene therapy/cell therapy modality was primarily developed by the National Cancer Institute (NCI) Surgery Branch for the treatment of metastatic melanoma. The therapeutic process involves isolating patient lymphocytes via leukapheresis, transducing them with the retroviral vector encoding the alpha and beta chains of the anti-gp100 TCR, and re-infusing the expanded cells into the patient following a lymphodepleting conditioning regimen. The engineered T cells are intended to specifically target and lyse melanoma cells overexpressing the gp100 protein.

Other names

gp100 TCR-transduced T cellsgp-100 TCR-transduced T cellsgp 100 TCR-transduced T cellsgp100-specific TCR-engineered T cellsgp-100-specific TCR-engineered T cellsgp 100-specific TCR-engineered T cellsanti-gp100 TCR-transduced lymphocytesanti-gp-100 TCR-transduced lymphocytesanti-gp 100 TCR-transduced lymphocytesgp100:154-162 TCR-transduced PBL